妈妈滤泡淋巴瘤一年半后复发

泽布替尼是BTK抑制剂的一种，一般联合CD20单抗治疗的数据更多一些。
对比单药治疗滤泡淋巴瘤的疗效：
我帮你查了一篇文献：
题目：

Advancements in Follicular Lymphoma Treatment With Targeted Therapies
Nov 14, 2024
By Morgan Bayer

The open-label, multicenter, phase 2 ROSEWOOD trial involved 217 adult patients with relapsed or refractory FL that had at lease 2 prior systemic therapies. Patients were randomly assigned 2:1 to receive zanubrutinib at a dose of 160 mg orally twice daily plus obinutuzumab at a dose of 1000 mg intravenously, or obinutuzumab alone at the same dosage and schedule. The treatment cycle was 28 days for both groups and obinutuzumab was given on days 1, 8, and 15 of cycle 1; day 1 of cycles 2 through 6; and once every 8 weeks until disease progression, toxicity, or a maximum of 2 years.

The overall response rate (ORR) was 68% in the experimental arm vs 43% in the obinutuzumab alone-arm (P = .001), and the complete response (CR) rate was 39% vs 19%, respectfully. The duration of response (DOR) was not reached in the experimental arm vs 26.5 months in the obinutuzumab alone-arm (HR, 0.5; P =.001).
上面可以看到，联合治疗的有效率68%要高于单药43%。

来自苹果APP客户端

aa加油加油123 · 发表于 2025-3-10 13:16:08

penny2024 发表于 2025-03-10 12:21
泽布替尼是BTK抑制剂的一种，一般联合CD20单抗治疗的数据更多一些。
对比单药治疗滤泡淋巴瘤的疗效：
我帮你查了一篇文献：
题目：

Advancements in Follicular Lymphoma Treatment With Targeted Therapies
Nov 14, 2024
By Morgan Bayer

The open-label, multicenter, phase 2 ROSEWOOD trial involved 217 adult patients with relapsed or refractory FL that had at lease 2 prior systemic therapies. Patients were randomly assigned 2:1 to receive zanubrutinib at a dose of 160 mg orally twice daily plus obinutuzumab at a dose of 1000 mg intravenously, or obinutuzumab alone at the same dosage and schedule. The treatment cycle was 28 days for both groups and obinutuzumab was given on days 1, 8, and 15 of cycle 1; day 1 of cycles 2 through 6; and once every 8 weeks until disease progression, toxicity, or a maximum of 2 years.

The overall response rate (ORR) was 68% in the experimental arm vs 43% in the obinutuzumab alone-arm (P = .001), and the complete response (CR) rate was 39% vs 19%, respectfully. The duration of response (DOR) was not reached in the experimental arm vs 26.5 months in the obinutuzumab alone-arm (HR, 0.5; P =.001).
上面可以看到，联合治疗的有效率68%要高于单药43%。

非常感谢你！

来自安卓APP客户端